AUS
NZ
UK
CA
USA
IND
Highlights
- Anteris subsidiary launches IPO for Nasdaq listing.
- Proceeds to fund heart valve development and global studies.
- Maintains connection to Australian roots via dual listing.
Anteris Technologies (ASX:AVR), an Australian-based leader in structural heart medical devices, has taken a significant step in its global expansion. Its subsidiary, Anteris Technologies Global Corp (ATGC), has launched a United States initial public offering (IPO), aiming to strengthen its presence in international markets through a Nasdaq listing.
The offering includes 14.8 million shares of common stock, with an additional 2.22 million shares available to underwriters as part of a 30-day option. This strategic move positions ATGC to attract global investors while driving advancements in the medical device sector. The Common Stock is set to trade on the Nasdaq Global Market under the ticker symbol ‘AVR.’
Supporting Innovation in Medical Devices
Proceeds from the IPO are planned to fund ongoing development of ATGC’s groundbreaking DurAVR® transcatheter heart valve (DurAVR® THV), leveraging the company’s proprietary ADAPT® anti-calcification tissue technology. This innovative valve mimics the functionality of a healthy human aortic valve, providing transformative care for patients with severe aortic stenosis.
Funds will also support the preparation and enrolment of a randomized global pivotal study for the DurAVR® THV, ensuring regulatory compliance and expanding clinical validation. Additional allocations are intended for working capital, general corporate purposes, and repayment of outstanding obligations under a convertible note facility.
A Strategic Step in Global Growth
The IPO marks a critical milestone for Anteris (AVR) as it continues to build a stronger footprint in the global capital markets. Alongside its Nasdaq debut, ATGC plans to maintain a connection to its Australian roots by listing CHESS Depositary Interests (CDIs) on the Australian Securities Exchange under the ticker symbol ‘AVR.’
This dual listing strategy reinforces the company’s commitment to its home market while attracting broader international support. With regulatory approvals in place, ATGC’s IPO reflects its ambitious roadmap for growth and innovation in the field of structural heart devices.
Regulatory Process and Market Debut
ATGC has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission to facilitate the offering. The company has clarified that no securities can be sold until the statement becomes effective, ensuring compliance with regulatory standards.
Based in Australia with operations in Minneapolis, Anteris continues to advance healthcare solutions for aortic stenosis, addressing critical needs in cardiovascular health through its cutting-edge technologies and global collaborations.
